Barclays Has Lowered Expectations for Progyny (NASDAQ:PGNY) Stock Price

Progyny (NASDAQ:PGNY) had its price target cut by investment analysts at Barclays from $29.00 to $23.00 in a research note issued on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price objective points to a potential upside of 26.86% from the stock’s previous close.

PGNY has been the subject of several other research reports. Canaccord Genuity Group decreased their price objective on shares of Progyny from $26.00 to $19.00 and set a “hold” rating for the company in a research note on Wednesday, March 11th. Weiss Ratings restated a “hold (c)” rating on shares of Progyny in a research note on Monday, December 29th. BTIG Research reduced their target price on Progyny from $35.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, March 5th. Truist Financial decreased their price target on Progyny from $34.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, March 2nd. Finally, Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a report on Saturday, January 3rd. Nine analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Progyny currently has an average rating of “Moderate Buy” and a consensus price target of $27.91.

Progyny Price Performance

PGNY opened at $18.13 on Friday. The company has a market capitalization of $1.48 billion, a price-to-earnings ratio of 27.89, a P/E/G ratio of 1.21 and a beta of 1.01. The firm’s fifty day moving average price is $21.40 and its two-hundred day moving average price is $22.55. Progyny has a 1 year low of $16.75 and a 1 year high of $28.75.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.10. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The firm had revenue of $318.40 million during the quarter, compared to analyst estimates of $314.26 million. During the same quarter in the prior year, the business posted $0.42 EPS. The business’s revenue was up 6.7% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, equities analysts anticipate that Progyny will post 0.6 EPS for the current year.

Insiders Place Their Bets

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the business’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80. Following the sale, the executive vice president owned 89,879 shares of the company’s stock, valued at $1,563,894.60. The trade was a 4.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last ninety days, insiders have sold 7,455 shares of company stock valued at $129,515. 9.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Progyny

Several hedge funds have recently made changes to their positions in PGNY. California State Teachers Retirement System boosted its stake in Progyny by 0.7% in the 2nd quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock worth $1,549,000 after purchasing an additional 457 shares during the period. Teza Capital Management LLC increased its position in shares of Progyny by 5.4% during the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock valued at $221,000 after buying an additional 516 shares during the period. Leibman Financial Services Inc. increased its position in shares of Progyny by 1.2% during the fourth quarter. Leibman Financial Services Inc. now owns 46,435 shares of the company’s stock valued at $1,192,000 after buying an additional 528 shares during the period. Aristides Capital LLC lifted its holdings in shares of Progyny by 4.6% in the third quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock worth $257,000 after buying an additional 528 shares in the last quarter. Finally, Oxford Asset Management LLP boosted its position in shares of Progyny by 4.3% in the second quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock valued at $284,000 after acquiring an additional 531 shares during the period. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.